Voriderm Powder For Suspension
Voriconazole
200gm/100ml
Incepta Pharmaceuticals Ltd.
| Pack size | 40ml |
|---|---|
| Unite Price | 1000.00 BDT |
Indications
Voriderm Powder For Suspension is used for:
Candidemia, Deep tissue Candida infections, Invasive aspergillosis, Scedosporiosis and Fusariosis
Adult Dose
Adult
Invasive Aspergillosis, Candidemia, Serious Fungal Infections
6 mg/kg IV q12hr for first 24 hours, then 4 mg/kg IV q12hr
or 200 mg PO q12hr
Esophageal Candidiasis
Candida albicans, Candida glabrata, Candida krusei
200 mg PO q12hr
Hepatic impairment: Mild to moderate (Child-Pugh category A and B): Standard loading dose but maintenance doses should be reduced by 50%.
Child Dose
<12 years: Safety and efficacy not established
Child >12 years
Invasive Aspergillosis, Candidemia, Serious Fungal Infections
6 mg/kg IV q12hr for first 24 hours, then 4 mg/kg IV q12hr
or 200 mg PO q12hr
Esophageal Candidiasis
Candida albicans, Candida glabrata, Candida krusei
200 mg PO q12hr
Renal Dose
Administration
Should be taken on an empty stomach. Take at least 1 hr before or after meals.
Infuse IV over 1-2 hr, not to exceed 3 mg/kg/hr
Contra Indications
Hypersensitivity. Co-admin w/ CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide, quinidine, rifampicin, carbamazepine, long-acting barbiturates (e.g. phenobarbital, mephobarbital), ergot alkaloids (e.g. ergotamine and dihydroergotamine), efavirenz (≥400 mg once daily), ritonavir (≥400 mg bid), sirolimus, rifabutin, St John's wort.
Precautions
Patient w/ potentially proarrhythmic conditions, risk for acute pancreatitis. Correct electrolyte disturbances e.g. hypokalaemia, hypomagnesaemia and hypocalcaemia prior to treatment. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive or operate machinery. Avoid intense or prolonged exposure to direct sunlight. Monitoring Parameters Monitor hepatic (prior and during treatment) and renal (during treatment) function, serum electrolytes, visual and pancreatic function.
Lactation: Not known if excreted in breast milk, a decision should be made whether to discontinue nursing or drug; weigh risk/benefit
Pregnancy-Lactation
Pregnancy
Therapy can cause fetal harm when administered to a pregnant woman; there are no available data on pregnant women; in animal reproduction studies, oral voriconazole was teratogenic in rats and embryotoxic in rabbits; if this drug used during pregnancy, or if patient becomes pregnant while taking drug, inform patient of potential hazard to fetus Lactation No data are available regarding presence of drug in human milk, the effects of voriconazole on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child or from underlying maternal condition
Contraception
Advise females of reproductive potential to use effective contraception during treatment
Lactation
No data are available regarding presence of drug in human milk, the effects of voriconazole on breastfed infant, or on milk production; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child or from underlying maternal condition
Interactions
Increased prothrombin time w/ oral anticoagulants. May increase plasma concentrations of ciclosporin and tacrolimus, long-acting opiates (e.g. oxycodone, methadone), NSAIDs (e.g. ibuprofen, diclofenac), omeprazole, short-acting opiates (e.g. alfentanil, fentanyl). Decreased voriconazole plasma concentration and increased phenytoin plasma concentrations when used concomitantly. May increase plasma concentration w/ oral contraceptives.
Potentially Fatal: May increase risk of QT prolongation or torsades de pointes w/ astemizole, cisapride, pimozide, quinidine and terfenadine. May increase risk of ergotism w/ ergot alkaloids (e.g. ergotamine and dihydroergotamine). May significantly increase plasma concentrations of sirolimus. Decreased plasma concentrations w/ rifampicin, carbamazepine, long-acting barbiturates (e.g. phenobarbital, mephobarbital), efavirenz (?400 mg once daily), ritonavir (?400 mg bid). Concomitant use may significantly increase rifabutin and decrease voriconazole plasma concentration.
Side Effects
Side effects of Voriconazole :
>10%
Visual changes (photophobia, color changes, increased or decreased visual acuity, or blurred vision occur in 21%)
1-10%
Tachycardia, Hypertension, Hypotension, Vasodilation, Peripheral edema, Fever, Chills, Headache, Hallucinations, Dizziness, Rash, Pruritus, Photosensitizing skin reactions, Hypokalemia, Hypomagnesemia, Nausea, Vomiting, Abdominal pain, Diarrhea, Xerostomia, Thrombocytopenia, Alkaline phosphatase increased, Serum transaminases increased, ALT/AST increased, Cholestatic jaundice, ARF
Mode of Action
Voriconazole is a triazole antifungal agent which inhibits cytochrome P450-dependent enzymes thereby inhibiting ergosterol synthesis in fungal cell membranes. It has a broad spectrum of activity against all Candida spp. including strains resistant to fluconazole), Aspergillus spp., Scedosporium spp., and Fusarium spp.
Note
Voriderm 200gm/100ml Powder For Suspension generic name is Voriconazole. Voriderm 200gm/100ml Powder For Suspension is manufactured by Incepta Pharmaceuticals Ltd.Voriderm is availble in all over Bangladesh.
Mes BD drug index information on Voriderm Powder For Suspension is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.